Regulation of ghrelin secretion by somatostatin analogs in rats

European Journal of Endocrinology

Volumn 152, Issue 6, 2005, Pages 887-894

  Silva, Antonio P ^a   Bethmann, Kerstin ^a   Raulf, Friedrich ^a   Schmid, Herbert A ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GHRELIN; MESSENGER RNA; OCTREOTIDE; PASIREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BLOOD ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DESENSITIZATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; HORMONAL REGULATION; HORMONE ACTION; HORMONE INHIBITION; HORMONE RELEASE; LOW DRUG DOSE; MALE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STOMACH;

ANIMALS; FASTING; GASTROINTESTINAL AGENTS; INJECTIONS, SUBCUTANEOUS; MALE; OCTREOTIDE; PEPTIDE HORMONES; RATS; RATS, INBRED LEW; RECEPTORS, SOMATOSTATIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SECRETORY RATE; SOMATOSTATIN; STOMACH;

EID: 21344474829     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.01914     Document Type: Article

References (38)

1. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H & Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999 402 656-660.
2. De Ambrogi M, Volpe S & Tamanini C. Ghrelin: central and peripheral effects of a novel peptidyl hormone. Medical Science Monitor 2003 9 RA217-RA224.
3. Cassoni P, Papotti M, Ghe C, Catapano F, Sapino A, Graziani A, Deghenghi R, Reissmann T, Ghigo E & Muccioli G. Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. Journal of Clinical Endocrinology and Metabolism 2001 86 1738-1745.
4. Toshinai K, Mondal MS, Nakazato M, Date Y, Murakami N, Kojima M, Kangawa K & Matsukura S. Upregulation of Ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration. Biochemical Biophysical Research Communications 2001 281 1220-1225.
5. Ariyasu H, Takaya K, Hosoda H, Iwakura H, Ebihara K, Mori K, Ogawa Y, Hosoda K, Akamizu T, Kojima M, Kangawa K & Nakao K. Delavcd short-term secretory regulation of ghrelin in obese animals: evidenced by a specific RIA for the active form of ghrelin. Endocrinology 2002 143, 3341-3350.
6. Tschop M, Smiley DL & Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000 407 908-913.
7. Horvath TL, Diano S, Sotonyi P, Heiman M & Tschop M. Minireview: ghrelin and the regulation of energy balance-a hypothalamic perspective. Endocrinology 2001 142 4163-4169.
8. Soriano-Guillen L, Barrus V, Campos-Barros A & Argente J. Ghrelin levels in obesity and anorexia nervosa: effect of weight reduction or recuperation. The Journal of Pediatrics 2004 144 36-42.
9. Marzullo P, Verti B, Savia G, Walker GE, Guzzaloni G, Tagliaferri M, Di Blasio A & Liuzzi A. The relationship between active ghrelin levels and human obesity involves alterations in resting energy expenditure. Journal of Clinical Endocrinology and Metabolism 2004 89 936-939.
10. Cummings DE, Clement K, Purnell JQ, Vaisse C, Foster KE, Frayo RS, Schwartz MW, Basdevant A & Weigle DS. Elevated plasma ghretin levels in Prader Willi syndrome. Nature Medicine 2002 8 643-644.
11. DelParigi A, Tschop M, Heiman ML, Salbe AD, Vozarova B, Sell SM, Bunt JC & Tataranni PA. High circulating ghrelin: a potential cause for hyperphagia and obesity in Prader-Willi syndrome. Journal of Clinical Endocrinology and Metabolism 2002 87 5461-5464.
12. Haqq AM, Farooqi IS, O'Rahilly S, Stadler DD, Rosenfeld RG, Pratt KL, LaFranchi SH & Purnell JQ. Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome. Journal of Clinical Endocrinology and Metabolism 2003 88 174-178.
13. Tsolakis AV, Portela-Gomes GM, Stridsberg M, Grimelius L, Sundin A, Eriksson BK, Oberg KE & Janson ET. Malignant gastric ghrelinoma with hyperghrelinemia. Journal of Clinical Endocrinology and Metabolism 2004 89 3739-3744.
14. Goldstone AP. Prader-With syndrome: advances in genetics, pathophysiology and treatment. Trends in Endocrinology and Metabolism 2004 15 12-20.
15. Shintani M, Ogawa Y, Ebihara K, Aizawa-Abe M, Miyanaga F, Takaya K, Hayashi T, Inoue G, Hosoda K, Kojima M, Kangawa K & Nakao K. Ghrelin. an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 2001 50 227-232.
16. Wren AM, Scal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, Dhillo WS, Ghatei MA & Bloom SR. Ghrelin enhances appetite and increases food intake in humans. Journal of Clinical Endocrinology and Metabolism 2001 86 5992-5995.
17. Papotti M, Cassoni P, Volante M, Deghenghi R, Muccioli G & Ghigo E. Ghrelin producing endocrine tumors of the stomach and intestine. Journal of Clinical Endocrinology and Metabolism 2001 86 5052-5059.
18. Corbetta S, Peracchi M, Cappiello V, Lania A, Lauri E, Vago L, Beck-Peccoz P & Spada A. Circulating ghrelin levels in patients with pancreatic and gastrointestinal neuroendocrine tumors: identification of one pancreatic ghrelinoma. Journal of Clinical Endocrinology and Metabolism 2003 88 3117-3120.
19. Broglio F, Gottero C, Van Koetsveld P, Prodam F, Destefanis S, Benso A, Gauna C, Hofland L, Arvat E, van der Lely AJ & Ghigo E. Acetylcholine regulates ghrelin secretion in humans. Journal of Clinical Endocrinology and Metabolism 2004 89 2429-2433.
20. Norrelund H, Hansen TK, Orskov H, Hosoda H, Kojima M, Kangawa K, Weeke J, Moller N, Christiansen JS & Jorgensen JO. Ghrclin immunareactivity in human plasma is suppressed by somaroslatin. Clinical Endocrinology 2002 57 539-546.
21. Broglio F, Koetsveld Pv P, Benso A, Gottero C, Prodam F, Papotti M, Muccioli G, Gauna C, Hofland L, Deghenghi R, Arvat E, Van Der Lety AG & Ghigo E. Ghrelin secretion is inhibited by either somatostatin or cortistatin in humans. Journal of Clinical Endocrinology and Metabolism 2002 87 4829-4832.
22. Newman CB, Melmed S, Snyder PJ, Young WF, Boyajy LD, Levy R, Stewart WN, Klibanski A, Molitch ME & Gaged RF. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients-a clinical research center study. Journal of Clinical Endocrinology and Metabolism 1995 80 2768-2775 [Erratum in Journal of Clinical Endocrinology and Metabolism 1995 80 3238].
23. Giustina A, Barkan A, Casanueva FF, Cavagnim F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K & Melmed S. Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2000 85 526-529.
24. Lewis I, Bauer W, Albert R, Chandramouli N, Pless J, Weckbecker G & Bruns C. A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. Journal of Medical Chemistry 2003 46 2334-2344.
25. Bruns C, Lewis I, Briner U, Meno-Tetang G & Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. European Journal of Endocrinology 2002 146 707-716.
26. Weckbecker G, Briner U, Lewis I & Bruns C. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology 2002 143 4123-4130.
27. Schmid HA & Schoeffter P. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 2004 80 47-50.
28. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD & Melmed S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. Journal of Clinical Investigation 1997 100 2386-2392.
29. Schwarting H, Koop H, Gellert G & Arnold R. Effect of starvation on endocrine cells in the rat stomach. Regulatory Peptides 1986 14 33-39.
30. Voyles NR, Awoke S, Wade A, Bhathena SJ, Smith SS & Recant L. Starvation increases gastrointestinal somatostatin in normal and obese Zucker rats: a possible regulatory mechanism. Hormone and Metabolic Research 1982 14 392-395.
31. Roca B, Fernandez-Valencia R & Arilla E. Effects of fasting and refeeding on somatostatin concentration and binding to cytosol from rabbit gastric mucosa. Gut 1988 29 642-646.
32. 5 and insulin in rat pancreatic beta-cells. Endocrinology 1999 140 3790-3796.
33. Flanagan DE, Evans ML, Monsod TP, Rife F, Heptulla RA, Tamborlane WV & Sherwin Rs. The influence of insulin on circulating ghrelin. American Journal of Physiology Endocrinology and Metabolism 2003 284 E313-F316.
34. Lippl F, Kircher F, Erdmann J, Allescher HD & Schusdziarra V. Effect of GIP, GLP-1, insulin and gastrin on ghrelin release in the isolated rat stomach. Regulatory Peptides 2004 119 93-98.
35. Kamegai J, Tamura H, Shimizu T, Ishii S, Sugibara H & Oikawa S. Effects of insulin, leptin, and glucagon on ghrelin secretion from isolated perfuscd rat stomach. Regulatory Peptides 2004 119 77-81.
36. Shimada M, Date Y, Mondal MS, Toshinai K, Shimbara T, Fukunaga K, Murakami N, Miyazato M, Kangawa K, Yoshimatsu H, Matsuo H & Nakazato M. Somatostatin suppresses ghrelin secretion from the rat stomach. Biochemical Biophysical Research Communications 2003 302 520-525.
37. Barkan AL, Dimaraki EV, Jessup SK, Symons KV, Ermolenko M & Jaffe CA. Ghrelin secretion in humans is sexually dimorphic, suppressed by somatostatin, and not affected by the ambient growth hormone levels. Journal of Clinical Endocrinology and Metabolism 2003 88 2180-2184.
38. Tan TM, Vanderpump M, Khoo B, Patterson M, Ghatei MA & Goldstone AP. Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader-Willi syndronic. Joural of Clinical Endocrinology and Metabolism 2004 89 4162-4165.